Health Care

Humana’s recent insider holdings, rising stock, & upbeat sentiment suggest management confidence—investors eye strategic growth amid healthcare market shifts.

Heron Therapeutics insider trading: CEO Collard’s 13,797‑share buy after selling RSUs signals confidence in short‑term prospects and a strategic shift ahead of new equity plans.

Heron Therapeutics insider buys reveal confidence in its biochronomer platform, fast‑track reformulations, and strong early‑stage clinical gains.

United Therapeutics insider trades signal confidence in its prostacyclin platform; balanced buys/sells show disciplined portfolio management amid FDA and payer milestones.

Insider CFO buy‑options at Axe Compute signal exec confidence, yet AI‑oncology stock remains volatile; investors weigh tech promise against sharp price decline and negative P/E.

Guardant Health insider trades signal steady confidence while its liquid‑biopsy tests, backed by FDA clearance and solid clinical data, advance precision oncology—yet rising debt and integration hurdles call for careful investment and clinical appra…

Ultragenyx insider buying signals confidence in its rare‑disease drugs, growth pipeline, and outcome‑based reimbursement strategy.

Ginkgo Bioworks insider buys 587 shares, signaling confidence amid modest valuation. Investors should watch earnings, regulatory updates, and competitive moves for future upside.

Insider Cao Jin holds 5,400 shares of Ascentage Pharma, backing the company’s pre‑clinical pipeline and RSU vestings that could boost long‑term value.

WaVe Life Sciences’ CSO boosts stake, signals Delaware shift—insider confidence backs orphan‑disease pipeline and future liquidity.